Support The Moscow Times!

Russia Clears Remdesivir Coronavirus Drugs Used in Trump’s Treatment

Remdesivir has been shown to shorten coronavirus recovery time by an average of four days. Sergei Kiselyov / Moskva News Agency

Russia has cleared two antiviral drugs called remdesivir for coronavirus treatment after doctors used the drugs to treat U.S. President Donald Trump, the Health Ministry announced Wednesday.

U.S. studies have said that biochemical firm Gilead Sciences’ remdesivir can shorten coronavirus recovery time by an average of four days but does not reduce deaths. Remdesivir was part of a “kitchen sink” of therapeutics administered to Trump after he was hospitalized with Covid-19 earlier this month.

“The Russian Health Ministry has registered two remdesivir antiviral drugs for the treatment of the new coronavirus infection (Covid-19),” it said in a statement.

“Registration licenses for domestic and imported drugs were issued Wednesday,” the Russian ministry added.

Remdesivir has received full approval in Japan and emergency use approval from the U.S. Food and Drug Administration, India and South Korea. Europe’s healthcare regulator recommended conditional approval for remdesivir this summer.

Remdesivir, which was initially intended as an Ebola drug, is estimated to cost more than $5,000 in the U.S. and less than $100 in India. 

The drug is currently administered through an IV, with research of an inhaler version currently underway.

Russia is the world’s fourth-most affected country with more than 1.35 million confirmed cases of Covid-19.

The country is currently experiencing a second coronavirus wave with new cases nearly tripling from around 5,000 to nearly 14,000 in the course of a month. It has registered two candidate coronavirus vaccines ahead of large-scale clinical trials, with a third potential vaccine expected to be approved in December. 

Read more

Independent journalism isn’t dead. You can help keep it alive.

The Moscow Times’ team of journalists has been first with the big stories on the coronavirus crisis in Russia since day one. Our exclusives and on-the-ground reporting are being read and shared by many high-profile journalists.

We wouldn’t be able to produce this crucial journalism without the support of our loyal readers. Please consider making a donation to The Moscow Times to help us continue covering this historic time in the world’s largest country.